69 filings
Page 2 of 4
424B5
b5wzaf3suisnjm
4 Oct 23
Prospectus supplement for primary offering
4:05pm
8-K
hvsjdo1qmpj523npu8zr
2 Oct 23
Other Events
9:41pm
424B5
2gdq8rdo0 to5jk
2 Oct 23
Prospectus supplement for primary offering
5:09pm
424B5
ekcrdee
2 Oct 23
Prospectus supplement for primary offering
5:07pm
S-3ASR
eoafi4w
2 Oct 23
Automatic shelf registration
4:01pm
8-K
uibypimg cig52m11qc
27 Sep 23
Regulation FD Disclosure
6:58am
8-K
uli5 l9a9h09bkyl
31 Jul 23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
4:29pm
8-K
y074oym2
28 Jul 23
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
4:35pm
8-K
ddysgpfp38onrf 1gt
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
8-K
b17m115c2 hoqarlpfcv
12 May 23
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
4:47pm
S-8
ojimyu08
12 May 23
Registration of securities for employees
4:42pm
8-K
on6h67i xqj
4 May 23
Departure of Directors or Certain Officers
5:15pm
8-K
vpb0us7u sxz
23 Mar 23
Investor Presentation March 2023
6:25pm
8-K
2r3hd39rtm8j5x9o juw
23 Mar 23
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
4:35pm
DEFA14A
f2tgb lh3xv6l9vnt
23 Mar 23
Additional proxy soliciting materials
4:30pm
DEF 14A
t2os5fzx15x2p7ephj
23 Mar 23
Definitive proxy
4:27pm
10-K
qovae7 skc
23 Mar 23
Annual report
4:17pm
8-K
kqxl0k6 ecaumk
10 Jan 23
Regulation FD Disclosure
10:29am